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replaced by parenteral drug addiction
or sexual transmission.4,5 It is not
surprising that prevention is the most
adequate and cost-effective control
measure for these patients. 
Treating chronic HCV before kidney
transplantation is currently not an
essential criteria for including HCV-
positive patients on the transplant
waiting list. However, risk of post-
transplant chronic hepatitis C and the
difficulty to treat it at this stage of the
chronic kidney disease have been
reported.6-11
Pegylated interferon and interferon +
ribavirin are better than conventional
interferon, according to clinical trials.
However, the differences are small.
Combining ribavirin and pegylated
interferon requires close follow-up
during haemodialysis given the severity
of the secondary effects. It has increased
the sustained viral response, although it
is still less in the population without
chronic kidney disease.12 This, along
with the difficulty of treating patients
with stages 4 and 5 chronic kidney
disease in predialysis, highlights the
importance of resolving the infection at
early kidney disease stages. 
Transjugular liver biopsy reduces the
risks of bleeding associated with this
procedure and the kidney patient,
although there is little evidence in the
literature.13,14 This technique also allows
the hepatic venous pressure gradient to
be measured, providing diagnostic and
prognostic data. 
Studies that determine whether the
association of protease inhibitors
(telaprevir, boceprevir) with interferon
and ribavirin is safe for kidney patients
and may increase viral response rates. 
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To the Editor, 
We read with great interest the contri-
bution by Heras, et al.1. They reported
a significant case that seemed not to
respond to intravenous (IV) cyclo-
phosphamide (CPM) induction treat-
ment at 1 g but to respond to increa-
sed CPM dose to 1.5 g. Reading the
case report, we wondered whether
CPM certainly induced the lupus fla-
re or other mechanisms were involved
in the pathogenesis. They speculated
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To the Editor, 
With regards our scientific letter,
“Cyclophosphamide-induced lupus
flare in diffuse proliferative lupus
nephropathy”1 we would like to thank
that the lupus flare might have been
due to the initial underdosing of
cyclophosphamide. This explanation
is plausible, but we would like to say
that lupus flares can occur during or
after stopping CPM treatment, sug-
gesting the possible pathomecha-
nisms of lupus flare.
In the immunological test after the
first treatment of IV CPM, the patient
had increased C3 level, but C4 was
decreased. According to a previous
study by Ho, et al.2, a decrease in C4
was associated with a concurrent in-
crease in renal disease activity (p =
0.02). A decrease in C4 was especially
associated with concurrent decreases
in the hematocrit levels (p = 0.009),
and previous increases in C3 were
also associated with a higher fre-
quency of decrease in platelet counts
(p = 0.02). These data show that the
renal and hematologic systemic lupus
erythematosus (SLE) activity and fla-
res are strongly associated with decre-
ased C4.
Recently, Finke, et al.3 demonstrated that
complement C4-deficient mice result in
elevated intravascular levels of apoptotic
DNA, targeted to the splenic marginal
zone where it accumulates and induces
type I interferon-gamma (IFN-γ). Type I
IFN-γ is important for the initiation and
potentiation of SLE activity and correla-
ted with the renal disease and the presen-
ce of cutaneous manifestations4.
Therefore, we suggest that CPM is not an
inducer but an inhibitor of lupus flare, and
decreases in C4 and increased type I IFN-
γ might play the central role in the deve-
lopment of lupus activity and flares. Ho-
wever, further studies are necessary to
elucidate the exact molecular roles of
complement deficiency and elevated le-
vels of IFN-γ. The potential therapeutic
antibodies directed to either type I IFN-γ
or IFN α chain of the receptor 1 (IF-
NAR1)/IFNAR2 should also be further
evaluated in the future.
1. Heras M, Saiz A, Fernández-Reyes MJ,
Sánchez R, Zurita P, Urrego C.
Cyclophosphamide-induced lupus flare in
Park at al for their contribution, and their
suggestions of the possible
immunological mechanisms involved in
a lupus flare. Although they question
whether cyclophosphamide really
induces the flare or whether other
mechanisms are involved, we would like
to clarify that the title of the English
version “Cyclophosphamide-induced
lupus flare” could lead readers to believe
that we consider that treatment with
cyclophosphamide induced the flare,
however, we wanted to communicate
exactly the opposite. Indeed, as was
reflected in the “Discussion” section,
cyclophosphamide treatment is the best
immunosuppressive agent, with the
best results in inducing remission in
severe forms of lupus nephropathy
(LN).2 As Park at al have pointed out in
their letter, the lupus flare may or may
not occur after cyclophosphamide
treatment. In our case, it was during the
cyclophosphamide induction period
(less than 15 days). The flare was
confirmed following the first
phosphamide dose. Therefore, after
having dismissed several causes (renal
vein thrombosis, infection, etc.), we
brought another cyclophosphamide
dose forward (the second dose was
1.5g), which caused clinical and
biochemical improvements, and the
patient went into remission. To date,
the patient has not had any further
flares. We would like to emphasise the
importance of the cyclophosphamide
administered: we used the Euro-Lupus
Nephritis Trial regime, 500mg every
15 days.3 In this patient the flare would
have been earlier, since the relapse
occurred less than 15 days with 1g of
the first dose of cyclophosphamide.
For that reason, before considering
cyclophosphamide treatment to be
ineffective, it is important to bear in
mind the dose that has been
administered. Finally, we must
highlight that we did not consider for
one moment that cyclophosphamide
induced the lupus flare. Given an error
in the English version, the English title
should have been: Flare lupic during
induction with cyclophosphamide
therapy in diffuse proliferative lupus
nephropathy.
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